{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:23:20Z","timestamp":1765959800030},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00393-014-1481-1","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T09:09:05Z","timestamp":1431335345000},"page":"322-328","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hyperurik\u00e4mie \u2013 mehr als Gicht"],"prefix":"10.1007","volume":"74","author":[{"given":"L.","family":"Sellin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.T.","family":"Kielstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"key":"1481_CR1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10157-011-0532-z","volume":"16","author":"Anzai","year":"2012","unstructured":"Anzai N, Jutabha P, Amonpatumrat-Takahashi S et al (2012) Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol 16:89\u201395","journal-title":"Clin Exp Nephrol"},{"key":"1481_CR2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0003319707303444","volume":"58","author":"Baker","year":"2007","unstructured":"Baker JF, Schumacher HR, Krishnan E (2007) Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 58:450\u2013457","journal-title":"Angiology"},{"key":"1481_CR3","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63","journal-title":"Arthritis Res Ther"},{"key":"1481_CR4","unstructured":"Bleyer AJ, Hart PS (1993) UMOD-associated kidney disease. GeneReviews (\u00a7\u00a7\u00a7 bitte erg\u00e4nzen \u00a7\u00a7\u00a7)"},{"key":"1481_CR5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","volume":"19","author":"Bobulescu","year":"2012","unstructured":"Bobulescu IA, Moe OW (2012) Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 19:358\u2013371","journal-title":"Adv Chronic Kidney Dis"},{"key":"1481_CR6","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2215\/CJN.01220211","volume":"6","author":"Bollee","year":"2011","unstructured":"Bollee G, Dahan K, Flamant M et al (2011) Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. Clin J Am Soc Nephrol 6:2429\u20132438","journal-title":"Clin J Am Soc Nephrol"},{"key":"1481_CR7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MAJ.0b013e3181db6e16","volume":"339","author":"Chang","year":"2010","unstructured":"Chang HY, Tung CW, Lee PH et al (2010) Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci 339:509\u2013515","journal-title":"Am J Med Sci"},{"key":"1481_CR8","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","volume":"39","author":"Crittenden","year":"2012","unstructured":"Crittenden DB, Lehmann RA, Schneck L et al (2012) Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol 39:1458\u20131464","journal-title":"J Rheumatol"},{"key":"1481_CR9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10157-005-0368-5","volume":"9","author":"Enomoto","year":"2005","unstructured":"Enomoto A, Endou H (2005) Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 9:195\u2013205","journal-title":"Clin Exp Nephrol"},{"key":"1481_CR10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","volume":"300","author":"Feig","year":"2008","unstructured":"Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924\u2013932","journal-title":"JAMA"},{"key":"1481_CR11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BOR.0b013e32834f049f","volume":"24","author":"Gibson","year":"2012","unstructured":"Gibson T (2012) Hyperuricemia, gout and the kidney. Curr Opin Rheumatol 24:127\u2013131","journal-title":"Curr Opin Rheumatol"},{"key":"1481_CR12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"Goicoechea","year":"2010","unstructured":"Goicoechea M, De Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388\u20131393","journal-title":"Clin J Am Soc Nephrol"},{"key":"1481_CR13","doi-asserted-by":"crossref","unstructured":"Grimaldi-Bensouda L, Alperovitch A, Aubrun E et al (2014) Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis","DOI":"10.1136\/annrheumdis-2012-202972"},{"key":"1481_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","volume":"58","author":"Halevy","year":"2008","unstructured":"Halevy S, Ghislain PD, Mockenhaupt M et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58:25\u201332","journal-title":"J Am Acad Dermatol"},{"key":"1481_CR15","doi-asserted-by":"crossref","unstructured":"Hediger MA, Johnson RJ, Miyazaki H et al (2005) Molecular physiology of urate transport. Physiology (Bethesda) 20:125\u2013133","DOI":"10.1152\/physiol.00039.2004"},{"key":"1481_CR16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"Hsu","year":"2009","unstructured":"Hsu CY, Iribarren C, Mcculloch CE et al (2009) Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169:342\u2013350","journal-title":"Arch Intern Med"},{"key":"1481_CR17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfu352","volume":"30","author":"Jing","year":"2015","unstructured":"Jing J, Kielstein JT, Schultheiss UT et al (2015) Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant 30:613\u2013621","journal-title":"Nephrol Dial Transplant"},{"key":"1481_CR18","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D et al (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28:2221\u20132228","journal-title":"Nephrol Dial Transplant"},{"key":"1481_CR19","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","volume":"13","author":"Kang","year":"2002","unstructured":"Kang DH, Nakagawa T, Feng L et al (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888\u20132897","journal-title":"J Am Soc Nephrol"},{"key":"1481_CR20","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"Res","author":"Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431\u20131446","journal-title":"Arthritis Care"},{"key":"1481_CR21","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"Res","author":"Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447\u20131461","journal-title":"Arthritis Care"},{"key":"1481_CR22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3346\/jkms.2014.29.8.1077","volume":"29","author":"Kim","year":"2014","unstructured":"Kim HA, Seo YI, Song YW (2014) Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. J Korean Med Sci 29:1077\u20131081","journal-title":"J Korean Med Sci"},{"key":"1481_CR23","doi-asserted-by":"crossref","first-page":"e000282","DOI":"10.1136\/bmjopen-2011-000282","volume":"2","author":"Krishnan","year":"2012","unstructured":"Krishnan E (2012) Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2:e000282","journal-title":"BMJ Open"},{"key":"1481_CR24","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"Krishnan","year":"2006","unstructured":"Krishnan E, Baker JF, Furst DE et al (2006) Gout and the risk of acute myocardial infarction. Arthritis Rheum 54:2688\u20132696","journal-title":"Arthritis Rheum"},{"key":"1481_CR25","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1001\/jama.2014.14484","volume":"312","author":"Kuo","year":"2014","unstructured":"Kuo CF, Grainge MJ, Mallen C et al (2014) Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA 312:2684\u20132686","journal-title":"JAMA"},{"key":"1481_CR26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/annrheumdis-2013-204067","volume":"74","author":"Kuo","year":"2013","unstructured":"Kuo CF, Grainge MJ, See LC et al (2013) Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan. Ann Rheum Dis 74(2):369\u2013374","journal-title":"Ann Rheum Dis"},{"key":"1481_CR27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3899\/jrheum.131159","volume":"41","author":"Levy","year":"2014","unstructured":"Levy GD, Rashid N, Niu F et al (2014) Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol 41:955\u2013962","journal-title":"J Rheumatol"},{"key":"1481_CR28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11926-012-0240-z","volume":"14","author":"Lipkowitz","year":"2012","unstructured":"Lipkowitz MS (2012) Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep 14:179\u2013188","journal-title":"Curr Rheumatol Rep"},{"key":"1481_CR29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.0105-2896.2009.00860.x","volume":"233","author":"Martinon","year":"2010","unstructured":"Martinon F (2010) Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 233:218\u2013232","journal-title":"Immunol Rev"},{"key":"1481_CR30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1053\/j.ajkd.2011.04.025","volume":"58","author":"Neri","year":"2011","unstructured":"Neri L, Rocca Rey LA, Lentine KL et al (2011) Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis 58:398\u2013408","journal-title":"Am J Kidney Dis"},{"key":"1481_CR31","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"Noman","year":"2010","unstructured":"Noman A, Ang DS, Ogston S et al (2010) Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375:2161\u20132167","journal-title":"Lancet"},{"key":"1481_CR32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/europace\/eut260","volume":"16","author":"Nyrnes","year":"2014","unstructured":"Nyrnes A, Toft I, Njolstad I et al (2014) Uric acid is associated with future atrial fibrillation: an 11-year follow-up of 6308 men and women \u2013 the Tromso Study. Europace 16:320\u2013326","journal-title":"Europace"},{"key":"1481_CR33","first-page":"199","volume":"68","author":"Pillinger","year":"2010","unstructured":"Pillinger MH, Goldfarb DS, Keenan RT (2010) Gout and its comorbidities. Bull NYU Hosp Jt Dis 68:199\u2013203","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"1481_CR34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","volume":"10","author":"Richette","year":"2014","unstructured":"Richette P, Perez-Ruiz F, Doherty M et al (2014) Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol 10:654\u2013661","journal-title":"Nat Rev Rheumatol"},{"key":"1481_CR35","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"Schumacher","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540\u20131548","journal-title":"Arthritis Rheum"},{"key":"1481_CR36","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (Hrsg) (2008) Arzneiverordnungs-Report 2008. Springer, Berlin Heidelberg New York","DOI":"10.1007\/978-3-540-69219-5"},{"key":"1481_CR37","doi-asserted-by":"crossref","unstructured":"Seminog OO, Goldacre MJ (2013) Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford) 52:2251\u20132259","DOI":"10.1093\/rheumatology\/ket293"},{"key":"1481_CR38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","volume":"73","author":"Sivera","year":"2014","unstructured":"Sivera F, Andres M, Carmona L et al (2014) Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73:328\u2013335","journal-title":"Ann Rheum Dis"},{"key":"1481_CR39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/qjmed\/hct083","volume":"106","author":"Stack","year":"2013","unstructured":"Stack AG, Hanley A, Casserly LF et al (2013) Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 106:647\u2013658","journal-title":"QJM"},{"key":"1481_CR40","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64:2529\u20132536","journal-title":"Arthritis Rheum"},{"key":"1481_CR41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00296-013-2857-2","volume":"34","author":"Tausche","year":"2014","unstructured":"Tausche AK, Christoph M, Forkmann M et al (2014) As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int 34:101\u2013109","journal-title":"Rheumatol Int"},{"key":"1481_CR42","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62:1060\u20131068","journal-title":"Arthritis Rheum"},{"key":"1481_CR43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3899\/jrheum.140462","volume":"92","author":"Van","year":"2014","unstructured":"Van Echteld IA, Van Durme C, Falzon L et al (2014) Treatment of gout patients with impairment of renal function: a systematic literature review. J Rheumatol Suppl 92:48\u201354","journal-title":"J Rheumatol Suppl"},{"key":"1481_CR44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1378\/chest.117.1.19","volume":"117","author":"Voelkel","year":"2000","unstructured":"Voelkel MA, Wynne KM, Badesch DB et al (2000) Hyperuricemia in severe pulmonary hypertension. Chest 117:19\u201324","journal-title":"Chest"},{"key":"1481_CR45","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/sj.ki.5002089","volume":"71","author":"Wolf","year":"2007","unstructured":"Wolf MT, Beck BB, Zaucke F et al (2007) The uromodulin C744G mutation causes MCKD2 and FJHN in children and adults and may be due to a possible founder effect. Kidney Int 71:574\u2013581","journal-title":"Kidney Int"},{"key":"1481_CR46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med 125:679\u2013687 e671","journal-title":"Am J Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1481-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-014-1481-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1481-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T18:35:26Z","timestamp":1566671726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-014-1481-1"}},"subtitle":["Auswirkung auf das kardiovaskul\u00e4re Risiko und die Niereninsuffizienz"],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1007\/s00393-014-1481-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}